Category Archives: MS Treatment

15-03-2012 18:11 Healthy Moments Episode# 2012-11 Main Channel: http://www.youtube.com Website: http://www.jimiatherton.com Twitter http://www.twitter.com Facebook: http://www.facebook.com Google+: plus.google.com Otherchannel: http://www.youtube.com Merch Store: http://www.zazzle.com ABC NEWS: Coke, Pepsi Skirt Cancer Warning Label abcnews.go.com MSNBC: Why Do Our Eyelids Get Heavy When We're Sleepy? bodyodd.msnbc.msn.com ABC News: Discovery Could Mean Fewer Chemo Side Effects| abcnews.go.com ABC News: Is An MS Drug The Next Treatment For Spinal Cord Injuries? abcnews.go.com Definitions: 4-MI (4MEI) [Caramel Coloring]:en.wikipedia.org Levator Muscle :en.wikipedia.org Mullers (Superior Tarsal): en.wikipedia.org Frontalis Muscle: en.wikipedia.org Gilenya: en.wikipedia.org Anti Inflammatory:en.wikipedia.org Go here to read the rest: Healthy Moments: Coke Cancer,Chemo, Heavy Eyelids - Video … Continue reading →

16-03-2012 18:16 CCSVI, Sclafani, AAC, American Access Care, Stanford, Hubbard, Multiple sclerosis, MS, Zamboni, Haskal, University of Maryland, MSVlogSupport, Irishbear76, liberation treatment, chronic cerebrospinal venous, vascular, veins, Haacke, Dr. Dake, JHU, Johns Hopkins, Georgetown University, Boston University, CBC, CTV, CTV W5, W5, News, MS News, Ginger MacQueen, tysabri, PML, Paolo Zamboni, Zivadinov, CTVD Study Originally posted here: CCSVI - Update, One Month Post Procedure - Video … Continue reading →

by AZIZA JACKSON The Daily Home Mallory Grace was diagnosed with multiple sclerosis in January and has since gotten busy online organizing Team Mallory MS Divas for the MS walk in Birmingham on April 14, and fundraising through her Facebook page. The Lincoln High School junior has been in and out of hospitals, subjected to tests, and as of recently, diagnosed with multiple sclerosis. After the initial shock I thought something was wrong. I thought this is wrong, kids are not supposed to get this, said Mallorys mother Mandy Hutto. But they soon found out that Mallory was one out of 8,000 teens and children diagnosed with MS in the United States. I didnt know what MS was, Mallory said. She said as soon as she was diagnosed, she researched MS and started reading about others experiences with the disease. After reading about others stories it really scared me, Mallory said. But when I went to Emily she told me she would take care of me. Dr. Emily Riser, who is an MS specialist at Brookwood Medical Center in Birmingham, has been working with Mallory since her diagnosis in January. See the original post here: Teen diagnosed with MS raising … Continue reading →

The Michigan Chapter of the National Multiple Sclerosis Society and those living with MS in Michigan have been working to build awareness about multiple sclerosis this week during Multiple Sclerosis Awareness Week. The organization also is promoting a Walk MS event planned for 10 a.m. April 21 at Central Middle School. People can visit http://www.walkMSmi.org to find out more about the three mile walk. Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system which interrupts the flow of information within the brain, and between the brain and body. Symptoms range from reduced or lost mobility to numbness and tingling to blindness and paralysis. Other symptoms include cognitive difficulty, fatigue and weakness. The progress, severity and specific symptoms of MS cannot be predicted. Most people are diagnosed between the ages of 20 and 50, with at least two to three times more women than men having the disease. MS affects more than 18,000 individuals in Michigan, 400,000 people in the U.S., and more than 2 million worldwide. "Advances in research are moving us closer to stopping the disease, restoring function and ending MS forever," a spokesperson said. "MS has moved from an untreatable disease in 1993 to … Continue reading →

Multiple Sclerosis is most common disabling neurological condition, affecting almost 100,000 Britons New drug approved from England and Wales but NOT Scotland By Jenny Hope PUBLISHED: 03:37 EST, 16 March 2012 | UPDATED: 04:43 EST, 16 March 2012 New hope: 50 young people are diagnosed with MS each week Thousands of people with MS could benefit from the first pill to treat the disabling disease. The NHS rationing body has approved the drug fingolimod which can halve relapses compared with standard interferon injections. Experts hoped the once-a-day pill will replace injections and hospital infusions for at least 5,000 sufferers a year. In its initial assessment, the National Institute for Health and Clinical Excellence (Nice) said the drug was not value for money despite admitting it works. But after considering extra evidence on its effectiveness Nice decided to give the go-ahead for use on the NHS. Dr Eli Silber, a consultant neurologist who leads the MS service for South London based at Kings College Hospital, and was involved in trials, said Read more: Multiple Sclerosis: World-first pill for MS to be offered to thousands of British patients … Continue reading →

At least 3,000 people in the UK with multiple sclerosis (MS) could benefit from the world's first pill for the condition. The National Institute for Health and Clinical Excellence (Nice) has issued new draft guidance recommending fingolimod (brand name Gilenya) on the NHS for some patients with a form of MS. The pill can help reduce the number of relapses in adults with highly active relapsing-remitting multiple sclerosis (RRMS), which is characterised by periods when symptoms worsen and then improve. The guidance, which is in its final draft form but has not yet been issued to the NHS, relates to people who have experienced an unchanged or increased relapse rate, or ongoing severe relapses, compared with the previous year. This is despite them taking other drugs such as beta interferons. The MS Society estimates around 3,000 patients in the UK could benefit, although it says the figure could be higher. Nice's new guidance reverses a previous version issued in December and follows extra information provided by doctors and the drug manufacturer, Novartis, agreeing to a discount scheme. Professor Carole Longson, director of the health technology evaluation centre at Nice, said: "The latest draft guidance from our committee recommends the NHS … Continue reading →

* EU medicines agency to update on Gilenya safety in April * Novartis says working with EMA to finalise drug label * UK's NICE (Milan: NICE.MI - news) backs drug as cost-effective in about-turn (Combines news from EU medicines agency and Britain's NICE) LONDON, March 16 (Reuters) - European regulators are still probing the safety of Novartis AG's multiple sclerosis pill Gilenya, one of the Swiss firm's top new drug hopes, delaying an expected update on the medicine until April. The European Medicines Agency (EMA) initially aimed to give an update on the medicine by March 16 but a spokeswoman said on Friday that the review had not yet been finalised. As a result, an announcement is now due on April 19 or 20. The delay leaves a question mark over the product, which has seen its prospects clouded by concern about serious heart problems. But there was also good news for Gilenya as Britain's healthcare cost-effectiveness watchdog NICE, in an about-turn, decided it was ready to recommend its use on the state health service. Gilenya, the first multiple sclerosis (MS) pill of its kind, is seen by analysts as a potential blockbuster with annual sales of $2 billion by … Continue reading →

* NICE (Milan: NICE.MI - news) recommends Gilenya for certain MS patients * Changes view on drug after Novartis presents new data * Endorsement comes ahead of EMA safety update on drug LONDON, March 16 (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its top new drug hopes, has been recommended for use in Britain's state health service after a change of heart by the country's healthcare cost-effectiveness watchdog. Friday's verdict from the National Institute for Health (Euronext: IXSHL.NX - news) and Clinical Excellence (NICE), whose opinions are also watched closely in other countries, is welcome news for a product that has run into problems recently. Later on Friday, the European Medicines Agency (EMA) - the body responsible for licensing Gilenya in Europe (Chicago Options: ^REURUSD - news) in March 2011 - is expected to give an update on the safety of the medicine, following an in-depth review. The safety probe was launched because of reports of heart problems in some patients and the death of one person in the United States within 24 hours of starting treatment. Gilenya represents a significant change in multiple sclerosis (MS) treatment, since existing drugs such as beta interferons and Elan (Berlin: DRX.BE … Continue reading →

LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its top new drug hopes, has been recommended for use in the state health service after a change of heart by the country's healthcare cost-effectiveness watchdog. Friday's verdict from the National Institute for Health and Clinical Excellence (NICE), whose opinions are also watched closely in other countries, is welcome news for a product that has run into problems recently. Later on Friday, the European Medicines Agency (EMA) - the body responsible for licensing Gilenya in Europe in March 2011 - is expected to give an update on the safety of the medicine, following an in-depth review. The safety probe was launched because of reports of heart problems in some patients and the death of one person in the United States within 24 hours of starting treatment. Gilenya represents a significant change in multiple sclerosis (MS) treatment, since existing drugs such as beta interferons and Elan and Biogen Idec's Tysabri must be injected. NICE initially said it was unclear if the new drug, which is known generically as fingolimod, was any better than existing treatments. It changed its mind after Novartis presented data showing the benefits of using Gilenya in a … Continue reading →

14-03-2012 14:00 Doctors still don't understand what causes MS, but Dr. Wanda Castro, a neurologist with the UConn Health Center, tells NBC Connecticut's Yvonne Nava that with early diagnosis and treatment, patients can avoid ending up in a wheelchair. Read the original post: The Mysteries of Multiple Sclerosis - Video … Continue reading →